Addressing the limitation of traditional cyclodextrins' poor water solubility, MovaType breaks through technical barriers with cutting-edge molecular engineering to develop a series of cyclodextrin derivatives, unleashing the full potential of molecular encapsulation technology. This product line employs proprietary substitution control technology to achieve structural optimization through precise substitution degree regulation.

Based on natural cyclodextrins, MovaType develops its derivative series via chemical modifications such as hydroxypropylation or methylation, marketed under the brand Movaflex™.